Biochemical markers for neurodegenerative conditions

Abstract

Provided herein is a method of bioassay for the quantification of peptide fragments relevant to neurodegenerative conditions. The method comprises cleaving a Tau protein by a secretase, such as ADAM10, to form a neo-epitope. The method comprises contacting a blood derived sample with an antibody specific for the neo-epitope and determining the level of binding of the antibody to peptide fragments comprising the neo-epitope in the sample. Neo-epitope containing peptide levels are found to be inversely correlated to cognitive function.

Description

The present invention relates to the development of biomarkers for neurodegenerative conditions or for neurodegeneration and more particularly to assays for detection of biochemical markers valuable for diagnostic purposes in Alzheimer's disease and prognosis of disease development, including biochemical markers indicative of response to treatment regimens.

Alzheimer's disease (AD), often referred to as Alzheimer's, is a progressive and ultimately fatal neurological condition mainly affecting people above the age of 65 years. Worldwide AD affects an estimated 35.6 million people (2009), and the number is expected to double every 20 years. In the US alone the costs of AD amount to more than $148 billion per year, and that number is in excess of $320 billion worldwide [3], and when comparing the costs related to care for dementia (of which AD is 50-75% of the cases), these clearly exceed the costs related to care for cancer and heart disease, underlining that AD is a severe societal burden both from an individual point-of-view, and from a health care point-of-view. Although the course of Alzheimer's disease is individual, there are common symptoms, of which the earliest often are cognitive, and mistakenly considered to due to increased age or stress [37]. Early symptoms include failing short term memory, and if suspected, behavioural assessments and cognitive tests, and if possible an MR-scan of the brain, are performed to strengthen the diagnosis [37]. As the disease progresses, symptoms include a series of neurological issues, such as confusion, irritability and aggression, language breakdown, long-term memory loss, leading the individuals to become introvert [2]. Finally, bodily functions begin breaking down, ultimately resulting in death, and the mean life expectancy following diagnosis is approximately seven years [2;28].

A major issue in relation to better treating and understanding AD, is that the early development of disease is veiled, and thus AD has often progressed for several years becoming fully apparent leading to diagnosis [13]. Furthermore, in most cases, an individual with the symptoms of AD will generally be diagnosed as a “probable” sufferer of the disease only when other possible causes for the symptoms have been ruled out. Although diagnostic criteria have been standardized through the use of intellectual function testing, it is still generally accepted that AD can only be diagnosed definitively by autopsy [27].

Recent studies have indicated that some progress has been made using biochemical markers as well as imaging techniques; however, these approaches still need further characterization and validation, and are often limited by lack of sensitivity in the early stages of development [24;33;34;38;39].

Currently used treatments offer a small palliative benefit; and treatments with the ability to slow down or prevent progression are a hotly pursued commodity, as illustrated by the fact that more than 500 clinical trials have been conducted for identification of a possible treatment for AD, and as of yet none have clearly identified a treatment possibility [1]. These data, together with the lack of established biomarkers of AD, clearly illustrate the necessity of investment into the development of biomarkers which can reflect more accurately important aspects of AD, such as disease onset, progression and response to therapy.

Assessment of Alzheimer's risk is close to impossible, except in the cases involving the APOE ε4 variant [8]. Furthermore, monitoring efficacy of trial drugs is possible, but often is attached directly to the mode of action of the drug, rather than to the overall pathology of AD [8].

Analysis of brain tissue from AD individuals has highlighted the disturbance of the extracellular matrix remodeling [12], mainly showing two important phenomena, namely the formation of plaques containing beta amyloid (Aβ), as well as the formation of Neurofibrillary Tangles containing a modified version of the Tau protein [10]. Both of these processes are highly relevant for disease progression, and interestingly deposition of Aβ in plaques precedes the actual neuronal damage [30], but is involving in triggering the formation of Neurofibrillary tangles [32], which appears to be the main reason for neuronal cell death [5;18]. APP is an integral membrane protein expressed in many tissues and concentrated in the synapses of neurons. Its primary function is not known, and it is most commonly studied as the precursor molecule of beta amyloid (Aβ), a 39- to 42-amino acid peptide, which when present in the amyloid fibrillar form is the primary component of amyloid plaques [10]. Aβ is produced from two proteolytic cleavages, first by β-secretase (BACE-1) and the second cleavage is performed by the γ-secretase. These sequential biochemical events are essential for Aβ formation [10]. Furthermore, other enzymatic cleavages, such as those by ADAM10 (A Disintegrin And Metalloproteinase 10) and presenilin-1, as well as other types of post-translational modifications of APP, result in modified peptide fragments of which the clinical significance has not yet been completely clarified, although they are expected to related to disease progression [10;11;19;25;40].

Tau proteins are microtubule stabilizing proteins, which are highly abundant in neurons of the central nervous system, whereas they are rare outside the CNS, and Tau is an important component in the formation of Neurofibrillary tangles in AD [10]. Furthermore, mutations in Tau are relevant for a panel of neurodegenerative disorders, referred to a Tauopathies; however, AD is by far the most common disease involving changes in Tau proteins [10;17]. Post-translational modifications, such as phosphorylation and enzymatic cleavage, have been shown to modulate the ability of Tau to stabilize the microtubules leading to formation of Neurofibrillary tangles, as well as potential formation of small toxic protein aggregates, which may contribute to neuronal death and thereby disease progression [10;19]. The MAPT (Microtubule Associated Protein Tau) gene for encoding tau protein is located on chromosome 17q21, containing 16 exons. The major tau protein in the human brain is encoded by 11 exons. Exons 2, 3 and 10 are alternatively spliced, allowing six combinations (2⁻3⁻10⁻; 2⁺3⁻10⁻; 2⁺3⁺10⁻; 2⁻3⁻10⁺; 2⁺3⁻10⁺; 2⁺3⁺10⁺). Thus, in the human brain, the tau proteins constitute a family of six isoforms with the range from 352-441 amino acids. They differ in either zero, one or two inserts of 29 amino acids at the N-terminal part (exon 2 and 3), and three or four repeat-regions at the C-terminal part exon 10 missing. So, the longest isoform in the CNS has four repeats (R1, R2, R3 and R4) and two inserts (441 amino acids total), while the shortest isoform has three repeats (R1, R3 and R4) and no insert (352 amino acids total) [20]. The MAPT gene has two haplogroups, H1 and H2, in which the gene appears in inverted orientations. Haplogroup H2 is common only in Europe and in people with European ancestry. Haplogroup H1 appears to be associated with increased probability of certain dementias, such as Alzheimer's disease. All of these isoforms are found in neurons; however, it is not clear to what extent the different isoforms play roles in the pathology of Alzheimer's disease [20].

The enzymes involved in Tau processing include caspases, thrombin, as well as other proteases highly relevant for tissue turnover in neurons, such as MMPs [4;10;10;14;15;19;26;29;31]. The present invention is however concerned with a further enzyme group, namely the secretases.

Three types of secretases exist, α, β and γ-secretases [10]. The enzymes referred to as secretases are classically associated with the extracellular cleavage of a protein, which in the context of Alzheimer's mainly has been related to cleavage of Amyloid Precursor Protein (APP) leading to the generation of Amyloid β, which is the major determinant of amyloid plaque formation [10]. These categories are defined by the site in the protein, at which they cleave APP, however, in terms of pathological relevance disturbances in the function of any of the three types of secretase are known to cause Alzheimer's like pathology [10;11;35;36].

• The list of enzymes includes:
• α-secretases include: ADAM9, 10, 17 (TACE), 19 and BACE2
• β-secretases include: BACE1 and 2
• γ-secretase complex: Presenilin 1 and/or 2, Nicastrin, Aph-1a, Aph1b and Pen-2.

Due to their described role as secretases the ability of these enzymes to degrade Tau has never been assessed. However, it is well-known that Tau is extensively processed during the progression of Alzheimer's disease [14;15;17;26;29]. The enzymes known to cleave Tau, and hence indicated to be involved in the induction of neuronal death include the caspase family and the calpains, and treatment of Tau with these enzymes leads to the generation of a series of well-described fragments, which are speculated to cause neuronal cell death [10;32].

We have now explored the possibility that secretase mediated cleavage of Tau would lead to the generation of fragments, which could be used as biomarkers of Alzheimer's diseases.

The present invention now provides in a first aspect a method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of a protein by a secretase, said method comprising contacting a sample comprising said peptide fragments with an immunological binding partner having specific binding affinity for a said neo-epitope and determining the level of binding of said immunological binding partner to peptide fragments in said sample, wherein said protein is a Tau protein.

The Tau protein may be from any mammalian, including rodent, e.g. mouse or rat, and also including dog or monkey, but is preferably human.

The neo-epitope is preferably one which is not formed by cleavage of Tau by the caspase family and/or the calpains.

Optionally, said immunological binding partner has specific binding affinity for peptide fragments comprising a C-terminal neo-epitope of a Tau protein. Alternatively, said immunological binding partner has specific binding affinity for peptide fragments comprising an N-terminal neo-epitope of a Tau protein.

The protein may be Tau-A or any other member of the Tau family. The neo-epitope may be common to two or more or all of the Tau proteins.

The neo-epitope may preferably be formed by cleavage of a Tau protein by ADAM10 or BASE-1. It may be formed by more than one secretase.

Said immunological binding partner preferably has specific binding affinity for a peptide fragment which comprises a neo-epitope formed by cleavage of a Tau protein by a protease giving any one of the following partial sequences of human Tau (Table 1):

SEQ ID NO 1
AAPPGQKGQAN
SEQ ID NO 2
AAPPGQKGQANAT
SEQ ID NO 3
APVPMPDL
SEQ ID NO 4
APVPMPDLK
SEQ ID NO 5
APVPMPDLK
SEQ ID NO 6
ASLAKQGL
SEQ ID NO 7
ATLADEVSASLAKQGL
SEQ ID NO 8
ATRIPA
SEQ ID NO 9
ATRIPAKTPPAPK
SEQ ID NO 10
ATRIPAKTPPAPKTPPSSGEPPK
SEQ ID NO 11
ATRIPAKTPPAPKTPPSSGEPPKSGDR
SEQ ID NO 12
ATRIPAKTPPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 13
DEAAGHVT
SEQ ID NO 14
DRKDQGGYT
SEQ ID NO 15
EAAGHVTQARMVSKSKD
SEQ ID NO 16
EAAGHVTQARMVSKSKDGTGSDDKKAKGAD
SEQ ID NO 17
EDHAGTYG
SEQ ID NO 18
EGDTDAGLK
SEQ ID NO 19
ENAKAKTDHGAEIVY
SEQ ID NO 20
ENAKAKTDHGAEIVYK
SEQ ID NO 21
EVMEDHAGTYG
SEQ ID NO 22
EVMEDHAGTYGLGDRKD
SEQ ID NO 23
EVMEDHAGTYGLGDRKD
SEQ ID NO 24
EVMEDHAGTYGLGDRKDQGGYTMHQDQEGD
SEQ ID NO 25
EVSASLAK
SEQ ID NO 26
EVSASLAKQGL
SEQ ID NO 27
GAAPPGQKGQAN
SEQ ID NO 28
GAAPPGQKGQANAT
SEQ ID NO 29
GEPPKSGDRSGYS
SEQ ID NO 30
GSPGTPGSRSRTPSLPTPPT
SEQ ID NO 31
GTPGSRSRTPSLPTPPTR
SEQ ID NO 32
HGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQL
SEQ ID NO 33
HKPGGGQVEVK
SEQ ID NO 34
HVPGGGNKKIE
SEQ ID NO 35
HVPGGGNKKIET
SEQ ID NO 36
HVPGGGSVQ
SEQ ID NO 37
IPAKTPPAPK
SEQ ID NO 38
IPAKTPPAPKTPPSSGEPPKSGDR
SEQ ID NO 39
IPAKTPPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 40
KAKTDHGAEIVYK
SEQ ID NO 41
KSKDGTGSDDKKAKGADGKTKIA
SEQ ID NO 42
KSPVVSGDTSPRHLS
SEQ ID NO 43
KTPPAPKTPPSSGEPPK
SEQ ID NO 44
KTPPAPKTPPSSGEPPKSGDR
SEQ ID NO 45
KTPPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 46
LAKQGL
SEQ ID NO 47
LATLADEVSASLAKQGL
SEQ ID NO 48
LKNVKSKIGSTENLKHQPGGGKVQIINKKLD
SEQ ID NO 49
LKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSK
SEQ ID NO 50
LPTPPTR
SEQ ID NO 51
LPTPPTREPKKVA
SEQ ID NO 52
LPTPPTREPKKVAVV
SEQ ID NO 53
MHQDQEGDTDAGLK
SEQ ID NO 54
MHQDQEGDTDAGLK
SEQ ID NO 55
MVDSPQLATLADEVSASLAKQGL
SEQ ID NO 56
NATRIPAKTPPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 57
NIHHKPGGGQVE
SEQ ID NO 58
NIHHKPGGGQVEVK
SEQ ID NO 59
PGSPGTPGSRSRTPS
SEQ ID NO 60
PMPDLK
SEQ ID NO 61
PPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 62
PPKSGDRSGYS
SEQ ID NO 63
PPTREPKKVA
SEQ ID NO 64
PSSGEPPKSGDRSGYS
SEQ ID NO 65
PVPMPDLK
SEQ ID NO 66
PVPMPDLK
SEQ ID NO 67
QARMVS
SEQ ID NO 68
QLATLADEVSASLAKQGL
SEQ ID NO 69
QTAPVPMPDL
SEQ ID NO 70
QTAPVPMPDLK
SEQ ID NO 71
QTAPVPMPDLK
SEQ ID NO 72
RENAKAKTDHGAEIVYK
SEQ ID NO 73
RIPAKTPPAPK
SEQ ID NO 74
RIPAKTPPAPKTPPS
SEQ ID NO 75
RIPAKTPPAPKTPPSSGEPPK
SEQ ID NO 76
RIPAKTPPAPKTPPSSGEPPKSGDR
SEQ ID NO 77
RIPAKTPPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 78
RKDQGGYTMHQD
SEQ ID NO 79
RKDQGGYTMHQDQEGDTD
SEQ ID NO 80
RTPPKSPSSA
SEQ ID NO 81
RTPPKSPSSAKSRL
SEQ ID NO 82
RTPPKSPSSAKSRLQ
SEQ ID NO 83
RTPSLPTPPT
SEQ ID NO 84
RTPSLPTPPTR
SEQ ID NO 85
RTPSLPTPPTREPK
SEQ ID NO 86
RTPSLPTPPTREPKKVA
SEQ ID NO 87
SASLAKQGL
SEQ ID NO 88
SEKLDF
SEQ ID NO 89
SGDTSPRHLS
SEQ ID NO 90
SGEPPKSGDRSGYS
SEQ ID NO 91
SLAKQGL
SEQ ID NO 92
SPGSPGTPGSR
SEQ ID NO 93
SPGSPGTPGSRS
SEQ ID NO 94
SPGSPGTPGSRSR
SEQ ID NO 95
SPGSPGTPGSRSRT
SEQ ID NO 96
SPGSPGTPGSRSRTPS
SEQ ID NO 97
SPGSPGTPGSRSRTPSLPTPPT
SEQ ID NO 98
SPGSPGTPGSRSRTPSLPTPPTR
SEQ ID NO 99
SPGTPGSRS
SEQ ID NO 100
SPGTPGSRSRTPSLPTPPTREPKKVA
SEQ ID NO 101
SPQLATLADEVSASLAKQGL
SEQ ID NO 102
SPRHLS
SEQ ID NO 103
SPSSAKSRL
SEQ ID NO 104
SPSSAKSRLQ
SEQ ID NO 105
SPVVSGDTSPRHLS
SEQ ID NO 106
SRSRTPSLPTPPTR
SEQ ID NO 107
SRTPSLPTPPT
SEQ ID NO 108
SRTPSLPTPPTREPK
SEQ ID NO 109
SRTPSLPTPPTREPKKVA
SEQ ID NO 110
STENLK
SEQ ID NO 111
TAPVPMPDL
SEQ ID NO 112
TAPVPMPDLK
SEQ ID NO 113
TAPVPMPDLK
SEQ ID NO 114
TAPVPMPDLKN
SEQ ID NO 115
TAPVPMPDLKNVK
SEQ ID NO 116
TLADEVSASLAKQGL
SEQ ID NO 117
TPPAPK
SEQ ID NO 118
TPPAPKTPPSSGEPPK
SEQ ID NO 119
TPPAPKTPPSSGEPPKSGDR
SEQ ID NO 120
TPPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 121
TPPKSPSSAK
SEQ ID NO 122
TPPKSPSSAKSRL
SEQ ID NO 123
TPPKSPSSAKSRLQ
SEQ ID NO 124
TPPSSGEPPKSGDR
SEQ ID NO 125
TPPSSGEPPKSGDRSGYS
SEQ ID NO 126
TPRGAAPPGQK
SEQ ID NO 127
TPRGAAPPGQKGQAN
SEQ ID NO 128
TPRGAAPPGQKGQANAT
SEQ ID NO 129
TPSLEDEAAGHVTQARMVSKSKD
SEQ ID NO 130
TRIPAKTPPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 131
TSPRHLSNVSSTGSID
SEQ ID NO 132
TSPRHLSNVSSTGSIDMVDSPQL
SEQ ID NO 133
TSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL
SEQ ID NO 134
VPGGGNKKIE
SEQ ID NO 135
VSASLAKQGL

where M indicates an oxidised methionine.Said immunological binding partner may have specific binding affinity for any of the following sequences at the N terminal of a peptide (Table 2):

AAPPGQ SEQ ID NO 136
APVPMP SEQ ID NO 137
APVPMP SEQ ID NO 138
ASLAKQ SEQ ID NO 139
ATLADE SEQ ID NO 140
ATRIPA SEQ ID NO 8
DEAAGH SEQ ID NO 141
DRKDQG SEQ ID NO 142
EAAGHV SEQ ID NO 143
EDHAGT SEQ ID NO 144
EGDTDA SEQ ID NO 145
ENAKAK SEQ ID NO 146
EVMEDH SEQ ID NO 147
EVMEDH SEQ ID NO 148
EVSASL SEQ ID NO 149
GAAPPG SEQ ID NO 150
GEPPKS SEQ ID NO 151
GSPGTP SEQ ID NO 152
GTPGSR SEQ ID NO 153
HGAEIV SEQ ID NO 154
HKPGGG SEQ ID NO 155
IPAKTP SEQ ID NO 156
KAKTDH SEQ ID NO 157
KSKDGT SEQ ID NO 158
KSPVVS SEQ ID NO 159
KTPPAP SEQ ID NO 160
LAKQGL SEQ ID NO 46
LATLAD SEQ ID NO 161
LKNVKS SEQ ID NO 162
LPTPPT SEQ ID NO 163
MHQDQE SEQ ID NO 164
MHQDQE SEQ ID NO 165
MVDSPQ SEQ ID NO 166
NATRIP SEQ ID NO 167
NIHHKP SEQ ID NO 168
PGSPGT SEQ ID NO 169
PMPDLK SEQ ID NO 60
PPAPKT SEQ ID NO 170
PPKSGD SEQ ID NO 171
PPTREP SEQ ID NO 172
PVPMPD SEQ ID NO 173
PVPMPD SEQ ID NO 174
QARMVS SEQ ID NO 67
QLATLA SEQ ID NO 175
QTAPVP SEQ ID NO 176
RENAKA SEQ ID NO 177
RIPAKT SEQ ID NO 178
RKDQGG SEQ ID NO 179
RTPPKS SEQ ID NO 180
RTPSLP SEQ ID NO 181
SASLAK SEQ ID NO 182
SEKLDF SEQ ID NO 88
SGDTSP SEQ ID NO 183
SGEPPK SEQ ID NO 184
SLAKQG SEQ ID NO 185
SPGSPG SEQ ID NO 186
SPQLAT SEQ ID NO 187
SPRHLS SEQ ID NO 102
SPSSAK SEQ ID NO 188
SPVVSG SEQ ID NO 189
SRSRTP SEQ ID NO 190
SRTPSL SEQ ID NO 191
STENLK SEQ ID NO 110
TAPVPM SEQ ID NO 192
TAPVPM SEQ ID NO 193
TLADEV SEQ ID NO 194
TPPAPK SEQ ID NO 117
TPPKSP SEQ ID NO 195
TPPSSG SEQ ID NO 196
TPRGAA SEQ ID NO 197
TPSLED SEQ ID NO 198
TRIPAK SEQ ID NO 199
TSPRHL SEQ ID NO 200
VPGGGN SEQ ID NO 201
VSASLA SEQ ID NO 202

where M indicates an oxidised methionine;or with any of the following sequences at the C-terminal of a peptide (Table 3):

AAGHVT SEQ ID NO 203
AEIVYK SEQ ID NO 204
AKSRLQ SEQ ID NO 205
APPGQK SEQ ID NO 206
ATRIPA SEQ ID NO 8
DLKNVK SEQ ID NO 207
DQGGYT SEQ ID NO 208
DRSGYS SEQ ID NO 209
EPKKVA SEQ ID NO 210
GAEIVY SEQ ID NO 211
GGGQVE SEQ ID NO 212
GGGSVQ SEQ ID NO 213
GKTKIA SEQ ID NO 214
GNKKIE SEQ ID NO 215
GQANAT SEQ ID NO 216
GQVEVK SEQ ID NO 217
GSRSRT SEQ ID NO 218
GTPGSR SEQ ID NO 153
HAGTYG SEQ ID NO 219
INKKLD SEQ ID NO 220
KAKGAD SEQ ID NO 221
KKVAVV SEQ ID NO 222
KSPSSA SEQ ID NO 223
LAKQGL SEQ ID NO 46
LGDRKD SEQ ID NO 224
LPTPPT SEQ ID NO 163
MPDLKN SEQ ID NO 225
NKKIET SEQ ID NO 226
PGSRSR SEQ ID NO 227
PKSGDR SEQ ID NO 228
PKTPPS SEQ ID NO 229
PMPDLK SEQ ID NO 60
PMPDLK SEQ ID NO 230
PTPPTR SEQ ID NO 231
PTREPK SEQ ID NO 232
QARMVS SEQ ID NO 67
QDQEGD SEQ ID NO 233
QEGDTD SEQ ID NO 234
QKGQAN SEQ ID NO 235
RSRTPS SEQ ID NO 236
SAKSRL SEQ ID NO 237
SASLAK SEQ ID NO 182
SEKLDF SEQ ID NO 88
SGEPPK SEQ ID NO 184
SNVQSK SEQ ID NO 238
SPRHLS SEQ ID NO 102
SPSSAK SEQ ID NO 188
STENLK SEQ ID NO 110
STGSID SEQ ID NO 239
TDAGLK SEQ ID NO 240
TPGSRS SEQ ID NO 241
TPPAPK SEQ ID NO 117
VDSPQL SEQ ID NO 242
VPMPDL SEQ ID NO 243
VSKSKD SEQ ID NO 244
YTMHQD SEQ ID NO 245

where M indicates an oxidised methionine.

Preferably, said immunological binding partner has specific binding affinity for the sequence TPRGAAPPGQ (SEQ ID NO 246) at the N terminal of a peptide.

Said immunological binding partner may be a monoclonal antibody or a fragment of a monoclonal antibody having specific binding affinity.

Said method may be conducted as a competition immunoassay in which said immunological binding partner and a competition agent are incubated in the presence of said sample and the competition agent competes with the peptide fragments in the sample to bind to the immunological binding partner. Said competition agent may be a synthetic peptide or is a purified native peptide formed by cleavage of the protein from which said epitope comes so as to reveal said neo-epitope and in particular may be a peptide comprising the N-terminal sequence TPRGAAPPGQ (SEQ ID NO 246).

The sample may be a sample of mammalian, e.g. mouse, rat, dog or monkey, but especially human cerebrospinal fluid, urine, serum, blood, plasma, or saliva. The sample may be a patient derived sample, said method further comprising comparing the determined level of said binding of said peptide fragments with values characteristic of (a) comparable healthy individuals and/or (b) a pathological neurodegenerative condition, particularly Alzheimer's. The measured level may be compared with a previous measurement obtained from the same patient.

In a further aspect, the invention includes an immunological binding partner against a C-terminal or N-terminal neo-epitope formed by secretase cleavage of a Tau protein. The immunological binding partner may be is specifically immunoreactive with the N-terminal of any one of the amino acid sequences of Table 2 or with the C-terminal of any one of the amino acid sequences of Table 3.

The immunological binding partner may be a monoclonal antibody or a binding fragment thereof. The invention includes a cell line producing such a monoclonal antibody or binding fragment.

In a further aspect, the invention includes a peptide comprising a C-terminal or N-terminal neo-epitope formed by cleavage of a Tau protein by a secretase at a terminal of any one of the partial sequences of a said Tau protein set out in Table 1. Said peptide may be conjugated as a hapten to a carrier for producing an immune response to said peptide, or immobilised to a solid surface or conjugated to a detectable marker for use in an immunoassay.

In a further aspect, the invention provides an isolated nucleic acid molecule coding for a peptide comprising a C-terminal or N-terminal neo-epitope formed by cleavage of a said Tau protein by a secretase in any one of the partial sequences of a said Tau protein set out in Table 1.

In a still further aspect, the invention provides a vector comprising a nucleic acid sequence comprising an expression signal and a coding sequence which codes for the expression of a peptide comprising a C-terminal or N-terminal neo-epitope formed by cleavage of a said Tau protein by a secretase in any one of the partial sequences of a said protein set out in Table 1.

In a still further aspect, the invention provides a host cell transformed with a vector as describe above and expressing a said peptide.

In a still further aspect, the invention provides an immunoassay kit comprising an immunological binding partner as describe and a competition agent which binds said immunological binding partner, and optionally one or more of a wash reagent, a buffer, a stopping reagent, an enzyme label, an enzyme label substrate, calibration standards, an anti-mouse antibody and instructions for conducting an assay using said kit.

The invention will be further explained and illustrated with reference to the accompanying drawings, in which:

FIG. 1 shows and example of a standard curve with either the selection peptide or the elongated peptide at concentrations of 0, 0.782, 1.5625, 3.125, 6.25, 12.5, 25, 50, and 100 ng/mL.

FIG. 2 shows competitive ELISA test results measured in extracted brains from either control or Tg4510 mice (a model of Alzheimer's disease).

FIGS. 3A-3B show Western blots comparing brain extracts from wt and Tg4510 mice. FIG. 3A) a western blot conducted with an antibody recognizing intact Tau (MAB3420 Chemicon). FIG. 3B) Western blot conducted with in house antibody (NB191).

FIG. 4 shows correlation of the levels of the ADAM10 generated Tau fragment in CSF and serum samples, showing that it can be monitored in both samples.

FIGS. 5A-5B show correlation of the Tau fragment to age, but not BMI.

FIG. 6 shows the ability of the Tau fragment level to follow progression of severe Alzheimer's in women.

FIGS. 7A-7F show results from Example 2 characterising and providing biological validation of the Tau-A assay. FIG. 7A) Standard curves with either the selection peptide or the elongated peptide at concentrations of 0, 0.59, 1.17, 2.34, 4.69, 9.38, 18.75, 37.5, 75, 150, and 300 ng/ml. FIG. 7B) Measurement of Tau-A fragments in in vitro digests of Tau. FIG. 7C) Western blots of extracted tissues, FIG. 7D) ELISA measurement of brain extracts in the presence or absence of ADAM10. FIG. 7E) Tau-A levels in extracted brains from either control or Tg4510mice (a model of Alzheimer's disease) measured using the ELISA. FIG. 7F) Western blots comparing brain extracts from wild type and Tg4510 mice. Left: a western blot conducted with an antibody recognizing intact Tau (MAB3420 Chemicon). Right: Western blot conducted with in-house antibody (NB191).

FIG. 8 shows pathology related changes in Tau-A levels demonstrating an inverse correlation between Tau-A and the Mattis Dementia Rating Scale (MDRS).

The following examples further explain and illustrate the invention.

EXAMPLE 1

In Vitro Cleavage

Recombinant TAU was cleaved either with activated ADAM10 or BACE1. Protease cleavage was performed by mixing 100 μg and 1 μg of enzyme (ADAM10 or BACE1) in secretase buffer (100 mM NaAcetate, pH 4.0) for 3 days. Finally the cleavage was verified by visualization using the SilverXpress® Silver Staining Kit (cat. no. LC6100, Invitrogen, Carlsbad, Calif., USA) according to the manufacturer's instructions.

Peptide Identification

Peptide fragments in the in vitro cleaved samples were identified using matrix-assisted laser desorption time of flight mass spectrometry (MALDI-TOF MS) and liquid chromatography coupled to electro spray ionization (ESI) tandem mass spectrometry (LC-MS/MS). MALDI-TOF samples were purified using C18 zip-tips (cat. no. ZTC18SO24, Millipore, Billerica, Mass., USA) according to specifications and 0.1 μg of material was eluted onto a MTP 384 ground steel target plate (Bruker-Daltonics, Bremen, Germany). MALDI tandem mass spectra were recorded on a Bruker ultraflex MALDI-TOF/TOF mass spectrometer (Bruker-Daltonics, Bremen, Germany) in positive ion reflector mode. Mass spectra were externally calibrated in the m/z range of 800-4000 using peptides generated by tryptic digestion of bovine β-lactoglobulin. The m/z software “Flexanalysis” (Bruker-Daltonics, Bremen, Germany) was used to analyze spectra. LCMS samples were ultra-filtrated to remove proteins above 10 kDa, the pH was adjusted to 2.0 using formic acid, and a 4 μL sample was analyzed by LC-MS/MS. LC was performed on a nanoACQUITY UPLC BEH C18 column (Waters, Milford, Mass., USA) using a formic acid/acetonitrile gradient. MS and MS/MS were performed on a Synapt High Definition Mass Spectrometry quadruple time of flight MS (QUAD-TOF; Waters, Milford, Mass., USA), with acquisition range of 350-1600 m/z in MS and 50-2000 m/z, in MS/MS. The software “ProteinLynx Global SERVER (PLGS)” (Waters, Milford, Mass., USA) was used to analyze spectra and generate peak lists. To identify peptides, MS and MS/MS data was searched against Tau (FASTA) protein database using the Mascot 2.2 (Matrix Science, Boston, Mass., USA) software with either the MALDI-TOF/TOF or ESI-QUAD-TOF settings.

The following peptide fragments were identified:

M indicates an oxidized methionine

Tau + BACE 1
Peptide
SEQ ID NO 46
LAKQGL
SEQ ID NO 91
SLAKQGL
SEQ ID NO 6
ASLAKQGL
SEQ ID NO 25
EVSASLAK
SEQ ID NO 87
SASLAKQGL
SEQ ID NO 135
VSASLAKQGL
SEQ ID NO 93
SPGSPGTPGSRS
SEQ ID NO 26
EVSASLAKQGL
SEQ ID NO 34
HVPGGGNKKIE
SEQ ID NO 21
EVMEDHAGTYG
SEQ ID NO 78
RKDQGGYTMHQD
SEQ ID NO 58
NIHHKPGGGQVEVK
SEQ ID NO 116
TLADEVSASLAKQGL
SEQ ID NO 7
ATLADEVSASLAKQGL
SEQ ID NO 131
TSPRHLSNVSSTGSID
SEQ ID NO 47
LATLADEVSASLAKQGL
SEQ ID NO 15
EAAGHVTQARMVSKSKD
SEQ ID NO 68
QLATLADEVSASLAKQGL
SEQ ID NO 22
EVMEDHAGTYGLGDRKD
SEQ ID NO 23
EVMEDHAGTYGLGDRKD
SEQ ID NO 101
SPQLATLADEVSASLAKQGL
SEQ ID NO 79
RKDQGGYTMHQDQEGDTD
SEQ ID NO 55
MVDSPQLATLADEVSASLAKQGL
SEQ ID NO 132
TSPRHLSNVSSTGSIDMVDSPQL
SEQ ID NO 129
TPSLEDEAAGHVTQARMVSKSKD
SEQ ID NO 16
EAAGHVTQARMVSKSKDGTGSDDKKAKGAD
SEQ ID NO 24
EVMEDHAGTYGLGDRKDQGGYTMHQDQEGD
SEQ ID NO 48
LKNVKSKIGSTENLKHQPGGGKVQIINKKLD
SEQ ID NO 32
HGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQL
SEQ ID NO 133
TSPRHLSNVSSTGSIDMVDSPQLATLADEVSASLAKQGL
SEQ ID NO 49
LKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSK
Tau + ADAM 10
Peptide
SEQ ID NO 117
TPPAPK
SEQ ID NO 8
ATRIPA
SEQ ID NO 67
QARMVS
SEQ ID NO 110
STENLK
SEQ ID NO 102
SPRHLS
SEQ ID NO 60
PMPDLK
SEQ ID NO 88
SEKLDF
SEQ ID NO 50
LPTPPTR
SEQ ID NO 13
DEAAGHVT
SEQ ID NO 36
HVPGGGSVQ
SEQ ID NO 3
APVPMPDL
SEQ ID NO 99
SPGTPGSRS
SEQ ID NO 17
EDHAGTYG
SEQ ID NO 65
PVPMPDLK
SEQ ID NO 18
EGDTDAGLK
SEQ ID NO 66
PVPMPDLK
SEQ ID NO 103
SPSSAKSRL
SEQ ID NO 111
TAPVPMPDL
SEQ ID NO 4
APVPMPDLK
SEQ ID NO 5
APVPMPDLK
SEQ ID NO 134
VPGGGNKKIE
SEQ ID NO 92
SPGSPGTPGSR
SEQ ID NO 121
TPPKSPSSAK
SEQ ID NO 37
IPAKTPPAPK
SEQ ID NO 80
RTPPKSPSSA
SEQ ID NO 1
AAPPGQKGQAN
SEQ ID NO 14
DRKDQGGYT
SEQ ID NO 89
SGDTSPRHLS
SEQ ID NO 104
SPSSAKSRLQ
SEQ ID NO 83
RTPSLPTPPT
SEQ ID NO 69
QTAPVPMPDL
SEQ ID NO 112
TAPVPMPDLK
SEQ ID NO 126
TPRGAAPPGQK
SEQ ID NO 113
TAPVPMPDLK
SEQ ID NO 93
SPGSPGTPGSRS
SEQ ID NO 27
GAAPPGQKGQAN
SEQ ID NO 26
EVSASLAKQGL
SEQ ID NO 63
PPTREPKKVA
SEQ ID NO 34
HVPGGGNKKIE
SEQ ID NO 33
HKPGGGQVEVK
SEQ ID NO 62
PPKSGDRSGYS
SEQ ID NO 107
SRTPSLPTPPT
SEQ ID NO 73
RIPAKTPPAPK
SEQ ID NO 114
TAPVPMPDLKN
SEQ ID NO 70
QTAPVPMPDLK
SEQ ID NO 2
AAPPGQKGQANAT
SEQ ID NO 71
QTAPVPMPDLK
SEQ ID NO 84
RTPSLPTPPTR
SEQ ID NO 35
HVPGGGNKKIET
SEQ ID NO 94
SPGSPGTPGSRSR
SEQ ID NO 28
GAAPPGQKGQANAT
SEQ ID NO 57
NIHHKPGGGQVE
SEQ ID NO 29
GEPPKSGDRSGYS
SEQ ID NO 95
SPGSPGTPGSRSRT
SEQ ID NO 9
ATRIPAKTPPAPK
SEQ ID NO 122
TPPKSPSSAKSRL
SEQ ID NO 115
TAPVPMPDLKNVK
SEQ ID NO 124
TPPSSGEPPKSGDR
SEQ ID NO 90
SGEPPKSGDRSGYS
SEQ ID NO 51
LPTPPTREPKKVA
SEQ ID NO 105
SPVVSGDTSPRHLS
SEQ ID NO 59
PGSPGTPGSRSRTPS
SEQ ID NO 127
TPRGAAPPGQKGQAN
SEQ ID NO 40
KAKTDHGAEIVYK
SEQ ID NO 123
TPPKSPSSAKSRLQ
SEQ ID NO 58
NIHHKPGGGQVEVK
SEQ ID NO 81
RTPPKSPSSAKSRL
SEQ ID NO 96
SPGSPGTPGSRSRTPS
SEQ ID NO 53
MHQDQEGDTDAGLK
SEQ ID NO 106
SRSRTPSLPTPPTR
SEQ ID NO 74
RIPAKTPPAPKTPPS
SEQ ID NO 54
MHQDQEGDTDAGLK
SEQ ID NO 42
KSPVVSGDTSPRHLS
SEQ ID NO 7
ATLADEVSASLAKQGL
SEQ ID NO 85
RTPSLPTPPTREPK
SEQ ID NO 118
TPPAPKTPPSSGEPPK
SEQ ID NO 64
PSSGEPPKSGDRSGYS
SEQ ID NO 128
TPRGAAPPGQKGQANAT
SEQ ID NO 52
LPTPPTREPKKVAVV
SEQ ID NO 82
RTPPKSPSSAKSRLQ
SEQ ID NO 19
ENAKAKTDHGAEIVY
SEQ ID NO 108
SRTPSLPTPPTREPK
SEQ ID NO 43
KTPPAPKTPPSSGEPPK
SEQ ID NO 20
ENAKAKTDHGAEIVYK
SEQ ID NO 125
TPPSSGEPPKSGDRSGYS
SEQ ID NO 31
GTPGSRSRTPSLPTPPTR
SEQ ID NO 86
RTPSLPTPPTREPKKVA
SEQ ID NO 72
RENAKAKTDHGAEIVYK
SEQ ID NO 30
GSPGTPGSRSRTPSLPTPPT
SEQ ID NO 109
SRTPSLPTPPTREPKKVA
SEQ ID NO 119
TPPAPKTPPSSGEPPKSGDR
SEQ ID NO 44
KTPPAPKTPPSSGEPPKSGDR
SEQ ID NO 97
SPGSPGTPGSRSRTPSLPTPPT
SEQ ID NO 75
RIPAKTPPAPKTPPSSGEPPK
SEQ ID NO 98
SPGSPGTPGSRSRTPSLPTPPTR
SEQ ID NO 61
PPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 41
KSKDGTGSDDKKAKGADGKTKIA
SEQ ID NO 10
ATRIPAKTPPAPKTPPSSGEPPK
SEQ ID NO 120
TPPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 38
IPAKTPPAPKTPPSSGEPPKSGDR
SEQ ID NO 45
KTPPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 76
RIPAKTPPAPKTPPSSGEPPKSGDR
SEQ ID NO 100
SPGTPGSRSRTPSLPTPPTREPKKVA
SEQ ID NO 11
ATRIPAKTPPAPKTPPSSGEPPKSGDR
SEQ ID NO 39
IPAKTPPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 77
RIPAKTPPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 130
TRIPAKTPPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 12
ATRIPAKTPPAPKTPPSSGEPPKSGDRSGYS
SEQ ID NO 56
NATRIPAKTPPAPKTPPSSGEPPKSGDRSGYS

Selection of Peptide for Immunizations

The first six amino acids of each free end of the sequences identified by MS were regarded as neo-epitopes generated by the protease in question. All obtained protease-generated sequences were analyzed for homology and distance to other cleavage sites and then blasted for homology using the NPS@: network protein sequence analysis.

Reagents and Peptides

All reagents were standard high-quality chemicals from companies such as Merck and Sigma Aldrich. The synthetic peptides used for monoclonal antibody production and validation were: (a) immunogenic peptide: TPRGAAPPGQ-GGC-KLH (SEQ ID NO 248-KLH) (Keyhole-Limpet-Hemocyanin), (b) screening peptide TPRGAAPPGQ (SEQ ID NO 246), (c) de-selection peptide ATPRGAAPPGQ (SEQ ID NO 247) which has been elongated with one amino acid in the N-terminus were purchased from Chinese Peptide Company, Beijing, China. Peptide conjugation reagents were produced by Pierce (Thermofisher, Denmark).

Buffers Used for the ELISAs

Buffer used for dissolving the coating peptide was composed of the following: (150 mM Trizma, 1% BSA, 0.05% Tween-20, 0.36% Bronidox L5, pH 8.0 (Tris-BTB), and reaction stopping buffer composed of 0.1% H₂SO₄.

ELISA-plates used for the assay development were Streptavidin-coated from Roche cat.: 11940279. All ELISA plates were analysed with the ELISA reader from Molecular Devices, SpectraMax M, (CA, USA).

Development of an ELISA

Methods for monoclonal antibody development are previously described ([6]. Briefly, 4-6-week-old Balb/C mice were immunized subcutaneously with 200 μl emulsified antigen and 50 μg TPRGAAPPGQ-GGC-KLH (SEQ ID NO 248-KLH). Consecutive immunizations were performed at 2-week intervals in Freund's incomplete adjuvant, until stable sera titre levels were reached, and the mice were bled from the 2nd immunization on. At each bleeding, the serum titre was detected and the mouse with highest antiserum titre was selected for fusion. The selected mouse was rested for 1 month followed by intravenous boosting with 50 ng TPRGAAPPGQ-GGC-KLH (SEQ ID NO 248-KLH) in 100 μl 0.9% Sodium Chloride solution 3 days before isolation of the spleen for cell fusion.

Fusion

The fusion procedure previously described [16] was followed with SP2/0 as myeloma cells. The fusion cells were cloned in 35-mm cell culture dishes by the semi-solid medium method and the dishes were incubated in a CO₂-incubator. Next, clones were plated into sixteen 96-well microtiter plates and left for three days, followed by screening of culture supernatants.

Antibody Screening

Supernatants were screened in a competitive ELISA setting. Peptide TPRGAAPPGQ (SEQ ID NO 246) was used as the selection peptide and the ATPRGAAPPGQ (SEQ ID NO 247) as the elongated peptide. Cell lines specific to selection peptide and without cross-reactivity to the elongated peptide were selected and the antibodies were purified.

Tau-A ELISA Methodology

In preliminary experiments, we optimized the reagents, their concentrations and the incubation periods by performing several checkerboard analyses. The Tau-A ELISA was developed as follows: A 96-well ELISA plate pre-coated with streptavidin was further coated with 6 ng/ml of the synthetic peptide TPRGAAPPGQ-Biotin (SEQ ID NO 246-Biotin) dissolved in Tris-BTB buffer at 20° C. for 30 min by constant shaking at 300 rpm. The plate was washed five times in washing buffer and 20 μl of sample was added, followed by 100 μl of peroxidase conjugated anti-human mAb-Tau-A solution (50 ng/ml). The plate was incubated for 1 h at 20° C. in 100 mM Tris-BTB buffer during which time it was shaken at 300 rpm.

The plate was again washed five times followed by addition of 100 μl tetramethylbenzinidine (TMB) (Kem-En-Tec cat. 438OH). The plate was incubated for 15 min in darkness and shaken at 300 rpm. In order to cease the reaction, 100 μl of stopping solution (95-97% H2SO4, Merck Cat. No.: 1.00731) was added and the plate was analysed in the ELISA reader at 450 nm with 650 nm as the reference.

Standards

A standard curve was performed by serial dilution of TPRGAAPPGQ-biotin (SEQ ID NO 246-biotin). Standard concentrations were 0, 0.782, 1.5625, 3.125, 6.25, 12.5, 25, 50, and 100 ng/ml.

Samples for Testing Native Reactivity of the Antibodies

During assay development and validation serum from healthy adult subjects of different age and gender were used. Serum samples are obtained from young healthy volunteers 23-45 years of age. We also tested serum samples from different species including mouse and rat to determine the level of interspecies cross reactivity. Finally, we also tested cerebrospinal Fluid (CSF) and plasma samples.

Animal Samples

Flash frozen brains from 5 wildtype and 5 Tg4510 Tauopathy mice aged 5 months [9] were extracted according to the following protocol:

The tissue was pulverized using a Bessman pulverizer and weighed. The tissue was extracted using 250 mg tissue/mL extraction buffer (50 mM Tris-HCl, 50 mM HEPES, 15% glycerol, 1 mM EDTA, 0.5% sodium deoxycholate, Roche protease inhibitor (cat#05 056 489001), final pH8.3). The lysate was cleared by sonication, and the supernatants were collected after centrifugation at 4° C./5 min/10000 rpm. Protein concentration was determined using the DC Protein Assay from BioRad.

Western Blotting

100 μg of each extract was loaded onto an SDS-PAGE gel. The gel was run and the samples were transferred to nitrocellulose membranes as described by [23]. The levels of Tau-A fragments and total Tau protein were detected by incubation with the primary antibodies diluted to 100 ng/mL in TBS-T containing skim milk powder [22]. A secondary antibody recognizing mouse IgG conjugated to horse-radish peroxidase was then used, and finally the blot was visualized using enhanced chemiluminescence as previously described [21].

Human Samples

Two sets of human samples were used. One set (51 samples) was a collection of serum samples from an osteoarthritis study, this study contained participants with ages from 18-75, as well as Body Mass Index data [7].

The second set of samples was paired serum and CSF samples from patients with severe Alzheimer's disease. These samples contained a subset of samples collected within the same individuals at baseline and follow-up (18 months later).

Statistical Analysis

For assay validation, optical density was fitted against analyte concentration applying a four-parameter logistic regression to the calibration curve. Average, standard deviations, percentage coefficient of variation (% CV), and differences from theoretical values were calculated for all standards and samples. Quantitative data were analysed using GraphPad Prism 5 (GraphPad Software, San Diego, Calif., USA). Significant differences between means were determined using the Student's two-tailed unpaired t-test, not assuming Gaussian distribution. Correlations between serum Tau values and the rest of the variables studied were analysed using Linear Regression. Data was expressed as mean±standard error of the mean and differences were considered significant at a p level of 0.05 or lower.

Results

ELISA Technical Specifications

The antibody with best native reactivity, affinity and stability in the assay was chosen from the antibody-producing clones generated after the fusion of spleen- and myeloma cells. The clone chosen for antibody purification and the subsequent development of the ELISA was NB191-3C4, raised against TPRGAAPPGQ (SEQ ID NO 246).

Standard Curve and Recovery

A typical standard curve is presented in FIG. 1, showing chosen standards and the 4-parametric fit equation for determination of sample concentration, based on peptide concentrations of 0, 0.782, 1.5625, 3.125, 6.25, 12.5, 25, 50, and 100 ng/mL. In addition the specificity of the antibody is shown by comparison to the same concentrations of the elongated peptide giving no reaction at all.

Determination of the linearity or recovery by dilution in different samples resulted in following. The average determined recoveries back-calculated from samples diluted 1+1, 1+2, 1+3, 1+4, 1+5, 1+6 and 1+7 to undiluted sample were close to 100% and within the recommended ±10% (data not shown).

Separation of Brains from Alzheimer's Mice and their Controls

The extracted brains from the Tg4510 mice and their corresponding controls were evaluated by measuring them in the NB191-3C4 ELISA setup. As seen in FIG. 2, a very clear separation was seen, with the Tg4510 showing 10-fold higher levels of Tau-A, when compared to the corresponding controls. In addition, a western blot was performed, and as seen in FIGS. 3A-3B the Tg4510 mice showed very high levels of Tau-A, while the control mice showed very little, even if equal amounts of protein were loaded (data not shown). On the other re-probing the blot with an antibody against total Tau showed almost equal levels of total Tau, although the intensity of the high molecular weight bands was higher in the Tg4510 correlating with Tau aggregation in this pathology.

Correlation of CSF and Serum Levels of Tau-A

In 33 paired samples of CSF and serum we investigated whether there was a correlation between Tau-A levels in the two analytes. As seen in FIG. 4 useful levels of Tau-A were detected in both analytes, and a modest, albeit not significant, correlation was observed.

Tau-A Correlates to Age, but not Body Mass Index

In the serum samples from the OA study, we performed an evaluation of Tau-A levels as a function of age and body mass index. Here we found a trend towards a positive correlation with age (FIG. 5A), but no correlation with BMI (FIG. 5B). These data indicate that Tau-A increases with age as a marker of Alzheimer's should.

Indication of Disease Progression

A subset of the serum samples from the Alzheimer's cohort was samples collected at baseline and 18 months later. Although these data only are from women, FIG. 6 shows a strong indication that in these 7 women, the levels of Tau-A increase from baseline to follow-up, hence indicating that Tau-A increases with increasing disease, as it is well-known that development of Alzheimer's is a continuous process.

EXAMPLE 2

Samples for Testing Native Reactivity of the Antibodies

For assay development and validation, serum and plasma from 15 healthy adult volunteers aged 23-45 years and of both genders were used. We also tested serum samples from mice and rats to determine the level of interspecies cross reactivity.

Animal Samples

Tissues including brain, liver, muscle, colon, kidney, lung, skin and pancreas isolated from 5 six-month-old Sprague Dawley rats and 5 brains from each of either the wildtype or Tg4510 mice were flash-frozen in liquid nitrogen and pulverized using a Bessman pulverizer. The “powder” was transferred to a vial and weighed. Extraction buffer (50 mM Tris-HCl, 50 mM HEPES, 1 mM EDTA, 0.5% sodium deoxycholate, 15% glycerol, protease inhibitor cocktail (Roche cat#05056489001), pH8.3) was added at 1 mL buffer/250 mg tissue. The lysate was cleared by sonication. After sonication the debris was spun at 4° C./5 min/10000 rpm and the supernatants were collected and stored at −80° C. until further use. Protein concentrations were determined using the DC Protein Assay (Biorad).

In Vitro Cleavage of Tissues

Protease cleavage was performed by mixing 100 μg of tissue extract and 1 μg of ADAM10 in MMP buffer (100 mM Tris-HCl, 100 mM NaCl, 10 mM CaCl₂, 2 mM Zn acetate, pH 8.0) and incubating for 7 days. Finally, the cleavage was verified by western blotting and ELISA analysis.

Western Blotting

20 μg of each rat tissue extract and 100 μg of each mouse tissue extract was loaded onto an SDS-PAGE gel. The gel was run and the samples were transferred to nitrocellulose membranes as previously described ¹⁵. Ponceau Red staining was then used to verify equal protein loading on the membranes. The levels of Tau-A fragments and total Tau protein were detected by incubation with the primary antibodies diluted to 100 ng/mL in TBS-T containing skim milk powder ¹⁵. A secondary antibody recognizing mouse IgG conjugated to horse-radish peroxidase was then added, and finally the blot was visualized using enhanced chemiluminescence as previously described ¹⁵.

Human Samples

Serum samples from Alzheimer's patients (n=21) were obtained. Characteristics: Age at onset 70(+/−7), Females/Males (16/6), baseline MDRS score 112(+/−12), Intact tau levels 849 (+/−1009).

Characterization of the Tau-A ELISA Assay

An antibody recognizing the ADAM10 generated cleavage sequence of Tau (TPRGAAPPGQ, SEQ ID NO 246) was selected and used for development of an ELISA (Tau-A). As seen in FIG. 7A, the assay was specific for the cleavage site, as extension of the sequence by one amino acid led to loss of reactivity. Further validation of specificity using ADAM10 degraded recombinant tau or brain extracts confirmed the specificity towards cleaved tau (FIG. 7B-C). In addition, tissue profiling confirmed that Tau primarily originates from the brain. The lower limit of detection (LLOD) was determined to be 2.9 ng/mL and the upper limit of detection (ULOD) was 226.3 ng/mL. The assay was technically robust and was able to detect Tau-A levels in human serum and plasma, as well as mouse and rat serum within dilution ranges of 1+2 to 1+6 (data not shown). In addition, a linear spiking recovery was obtained within the above described dilution ranges (data not shown). The intra-assay coefficient of variation was 5.8%, while the inter-assay CV % was 12.6%. No loss of reactivity was observed following 5 consecutive freeze-thaw cycles.

Biological Validation of the Tau-A ELISA

Analysis using the ELISA revealed that Tg4510 mice brains had 10-fold higher levels of Tau-A than their corresponding wt. controls (FIG. 7E). Western blotting also showed that Tg4510 mice had very high levels of Tau-A, while the control mice had very little (FIG. 7F). Re-probing the blot with an antibody against total Tau showed almost equal levels of total Tau, although the intensity of the high molecular weight bands was greater in the Tg4510.

Tau-A Levels Correlate with MDRS Score

To investigate whether a relationship between the marker and AD disease stage could be identified, we correlated the Tau-A levels in the AD patients to scores obtained using the Mattis Dementia Rating Scale ¹⁰, and found a significant (p=0.003) and inverse relationship between MDRS and Tau-A (FIG. 8). No correlations to other parameters, such as intact Tau in CSF or age could be observed in this cohort (data not shown).

Discussion

Potential serum and/or plasma-based markers for AD have been investigated extensively, yet a single biomarker with a correlation to cognitive function previously remained to be identified ^1-3. This, to our knowledge, is the first biochemical marker monitoring proteolytic processing of Tau in serum, which appears to be a key initiator of AD pathology ⁹. It is also the first single serum biomarker of a brain specific protein which correlates to cognitive function. While neo-epitopes have been extensively investigated in AD, as measurements of Aβ42 and phosphorylated Tau have been reported as neo-epitopes formed as a consequence of disease ⁴, selective screening of serum for in vitro generated Tau fragments had not previously been undertaken.

The combination of ADAM10 and Tau selected for this work was based on the novel hypothesis that during progression of AD, Tau will be exposed to secretase-mediated cleavage either directly in the brain or as fragments generated by other brain proteases, which then become secondarily processed as they enter the circulation; however, this requires further studies. We were able to detect a specific ADAM10-generated Tau peptide fragment in serum, as well as highly elevated levels in the brains of the Tg4510 mice. These observations suggest ADAM10 processing of Tau is a relevant process in neuronal death during AD, although the exact mechanism of action still remains to be identified.

In summary, we have developed the first serum-based assay detecting pathological fragments of Tau. This fragment was directly and inversely related to cognitive function. The assay provides a useful and practical tool for the diagnosis of neuronal loss, and can be used to monitor the efficacy of treatments and progression of AD.

In this specification, unless expressly otherwise indicated, the word ‘or’ is used in the sense of an operator that returns a true value when either or both of the stated conditions is met, as opposed to the operator ‘exclusive or’ which requires that only one of the conditions is met. The word ‘comprising’ is used in the sense of ‘including’ rather than in to mean ‘consisting of’. All prior teachings acknowledged above are hereby incorporated by reference. No acknowledgement of any prior published document herein should be taken to be an admission or representation that the teaching thereof was common general knowledge in Australia or elsewhere at the date hereof.

REFERENCE LIST

• 1. Alzheimer's Disease Clinical Trials. 2010. US National Institutes of Health & http://www.clinicaltrials.gov/ct2/results?term=alzheimer. Ref Type: Generic
• 2. Understanding stages and symptoms of Alzheimer's disease. 2010. www.nia.nih.gov/Alzheimers/Publications/stages.htm. Ref Type: Generic
• 3. World Alzheimer Report 2009. 2010. Alzheimer's Disease International. Ref Type: Generic
• 4. Arai T, Guo J P, McGeer P L (2005) Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. J. Biol. Chem. 280:5145-5153
• 5. Arriagada P V, Growdon J H, Hedley-Whyte E T, Hyman B T (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42:631-639
• 6. Barascuk N, Veidal S S, Larsen L, Larsen D V, Larsen M R, Wang J, Zheng Q, Xing R, Cao Y, Rasmussen L M, Karsdal M A (2010) A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin. Biochem. 43:899-904
• 7. Bay-Jensen A C, Liu Q, Byrjalsen I, Li Y, Wang J, Pedersen C, Leeming D J, Dam E B, Zheng Q, Qvist P, Karsdal M A (2011) Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM—increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin. Biochem. 44:423-429
• 8. Cummings J L (2011) Biomarkers in Alzheimer's disease drug development. Alzheimers. Dement. 7:e13-e44
• 9. de C A, Spires-Jones T L, Pitstick R, Carlson G A, Hyman B T (2009) Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy. J. Neuropathol. Exp. Neurol. 68:757-761
• 10. De S B (2010) Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev. 90:465-494
• 11. De S B, Annaert W (2000) Proteolytic processing and cell biological functions of the amyloid precursor protein. J. Cell Sci. 113 (Pt 11):1857-1870
• 12. Fillit H, Leveugle B (1995) Disorders of the extracellular matrix and the pathogenesis of senile dementia of the Alzheimer's type. Lab Invest 72:249-253
• 13. Forstl H, Kurz A (1999) Clinical features of Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci. 249:288-290
• 14. Gamblin T C, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet A L, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry R W, Binder L I, Cryns V L (2003) Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A 100:10032-10037
• 15. Garcia-Sierra F, Mondragon-Rodriguez S, Basurto-Islas G (2008) Truncation of tau protein and its pathological significance in Alzheimer's disease. J. Alzheimers. Dis. 14:401-409
• 16. Gefter M L, Margulies D H, Scharff M D (1977) A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic. Cell Genet. 3:231-236
• 17. Goedert M, Spillantini M G, Jakes R, Rutherford D, Crowther R A (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3:519-526
• 18. Gomez-Isla T, Hollister R, West H, Mui S, Growdon J H, Petersen R C, Parisi J E, Hyman B T (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41:17-24
• 19. Haass C, Selkoe D J (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8:101-112
• 20. Hanger D P, Wray S (2010) Tau cleavage and tau aggregation in neurodegenerative disease. Biochem. Soc. Trans. 38:1016-1020
• 21. Henriksen K, Gram J, Schaller S, Dahl B H, Dziegiel M H, Bollerslev J, Karsdal M A (2004) Characterization of osteoclasts from patients harboring a G215R mutation in C1C-7 causing autosomal dominant osteopetrosis type II. Am J Pathol 164:1537-1545
• 22. Henriksen K, Gram J, Schaller S, Dahl B H, Dziegiel M H, Bollerslev J, Karsdal M A (2004) Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing autosomal dominant osteopetrosis type II. Am J Pathol 164:1537-1545
• 23. Henriksen K, Gram J, Schaller S, Dahl B H, Dziegiel M H, Bollerslev J, Karsdal M A (2004) Characterization of osteoclasts from patients harboring a G215R mutation in C1C-7 causing autosomal dominant osteopetrosis type II. Am J Pathol 164:1537-1545
• 24. Hoglund K, Hansson O, Buchhave P, Zetterberg H, Lewczuk P, Londos E, Blennow K, Minthon L, Wiltfang J (2008) Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides. Neurodegener. Dis. 5:268-276
• 25. Jin S, Agerman K, Kolmodin K, Gustafsson E, Dahlqvist C, Jureus A, Liu G, Falting J, Berg S, Lundkvist J, Lendahl U (2010) Evidence for dimeric BACE-mediated APP processing. Biochem. Biophys. Res. Commun. 393:21-27
• 26. Kim B, Backus C, Oh S, Hayes J M, Feldman E L (2009) Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 150:5294-5301
• 27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E M (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34:939-944
• 28. Molsa P K, Marttila R J, Rinne U K (1986) Survival and cause of death in Alzheimer's disease and multi-infarct dementia. Acta Neurol. Scand. 74:103-107
• 29. Park S Y, Tournell C, Sinjoanu R C, Ferreira A (2007) Caspase-3- and calpain-mediated tau cleavage are differentially prevented by estrogen and testosterone in beta-amyloid-treated hippocampal neurons. Neuroscience 144:119-127
• 30. Polyikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinisto L, Halonen P, Kontula K (1995) Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N. Engl. J. Med. 333:1242-1247
• 31. Rametti A, Esclaire F, Yardin C, Terro F (2004) Linking alterations in tau phosphorylation and cleavage during neuronal apoptosis. J. Biol. Chem. 279:54518-54528
• 32. Reifert J, Hartung-Cranston D, Feinstein S C (2011) Amyloid {beta}-Mediated Cell Death of Cultured Hippocampal Neurons Reveals Extensive Tau Fragmentation without Increased Full-length Tau Phosphorylation. J. Biol. Chem. 286:20797-20811
• 33. Schroeter M L, Stein T, Maslowski N, Neumann J (2009) Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients. Neuroimage. 47:1196-1206
• 34. Takeda S, Sato N, Rakugi H, Morishita R (2010) Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease. Mol. Biosyst.
• 35. Vassar R, Kandalepas P C (2011) The beta-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease. Alzheimers. Res. Ther. 3:20
• 36. Vincent B, Checker F (2011) alpha-Secretase in Alzheimer's Disease and Beyond: Mechanistic, Regulation and Function in the Shedding of Membrane Proteins. Curr. Alzheimer Res.
• 37. Waldemar G, Dubois B, Emre M, Georges J, McKeith I G, Rossor M, Scheltens P, Tariska P, Winblad B (2007) Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur. J. Neurol. 14:e1-26
• 38. Zetterberg H (2008) Biomarkers reflecting different facets of Alzheimer's disease. Eur. J. Neurol. 15:1143-1144
• 39. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson M E, Buchhave P, Londos E, Umek R M, Minthon L, Simon A J, Blennow K (2008) Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch. Neurol. 65:1102-1107
• 40. Zhang S, Salemi J, Hou H, Zhu Y, Mori T, Giunta B, Obregon D, Tan J (2010) Rapamycin promotes beta-amyloid production via ADAM-10 inhibition. Biochem. Biophys. Res. Commun.

Claims

1. A method of detecting fragments of Tau protein formed by secretase cleavage of Tau protein in a human patient, said method comprising: a. obtaining a sample from the human patient; andb. detecting whether said fragments of Tau are present in the sample by contacting the sample with an antibody and detecting binding between the fragments and the antibodywherein said antibody is raised against a synthetic peptide corresponding to a C-terminal or N-terminal neo-epitope amino acid sequence formed by cleavage of Tau protein by a secretase and has specific binding affinity for said C-terminal or N-terminal neo-epitope amino acid sequence, and wherein said antibody has specific binding affinity for any of the following sequences at the N terminal of a peptide:

2. The method of claim 1, wherein the neo-epitope is formed by cleavage of a Tau protein by ADAM10 or BASE-1.

3. The method of claim 1, wherein said antibody has specific binding affinity for the following sequence at the N terminal of a peptide: TPRGAAPPGQ (SEQ ID NO 246).

4. The method of claim 1, wherein said antibody is a monoclonal antibody or a fragment of a monoclonal antibody having specific binding affinity.

5. The method of claim 1, wherein said method is conducted as a competition immunoassay in which said antibody and a competition agent are incubated in the presence of said sample and the competition agent competes with the peptide fragments in the sample to bind to the antibody.

6. The method of claim 5, wherein said competition agent is a synthetic peptide or is a purified native peptide formed by cleavage of the protein from which said epitope comes so as to reveal said neo-epitope.

7. The method of claim 6, wherein said competition agent comprises a peptide comprising the N-terminal sequence TPRGAAPPGQ (SEQ ID NO 246).

8. The method of claim 1, wherein the sample is a sample of urine, serum, blood, plasma, or saliva.